[{"orgOrder":0,"company":"Zhejiang Hisun Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"HS387","moa":"KIF18A","graph1":"Oncology","graph2":"Phase I","graph3":"Zhejiang Hisun Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zhejiang Hisun Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Zhejiang Hisun Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Zhejiang Hisun Pharmaceutical","sponsor":"Tigermed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Zhejiang Hisun Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zhejiang Hisun Pharmaceutical \/ Tigermed","highestDevelopmentStatusID":"10","companyTruncated":"Zhejiang Hisun Pharmaceutical \/ Tigermed"},{"orgOrder":0,"company":"Zhejiang Hisun Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Zhejiang Hisun Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zhejiang Hisun Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zhejiang Hisun Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Zhejiang Hisun Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Zhejiang Hisun Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zhejiang Hisun Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zhejiang Hisun Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Zhejiang Hisun Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"HS022","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Zhejiang Hisun Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zhejiang Hisun Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zhejiang Hisun Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Zhejiang Hisun Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"HS269","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Zhejiang Hisun Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zhejiang Hisun Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Zhejiang Hisun Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Zhejiang Hisun Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"HS628","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Zhejiang Hisun Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zhejiang Hisun Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zhejiang Hisun Pharmaceutical \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals by Zhejiang Hisun Pharmaceutical

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          BioJapan
                          Not Confirmed
                          BioJapan
                          Not Confirmed

                          Details : HS387 is a drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          July 30, 2025

                          Lead Product(s) : HS387

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          BioJapan
                          Not Confirmed
                          BioJapan
                          Not Confirmed

                          Details : HS022 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Breast Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          October 30, 2023

                          Lead Product(s) : HS022

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          BioJapan
                          Not Confirmed
                          BioJapan
                          Not Confirmed

                          Details : HS628 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Arthritis, Rheumatoid.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          September 21, 2023

                          Lead Product(s) : HS628

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          BioJapan
                          Not Confirmed
                          BioJapan
                          Not Confirmed

                          Details : HS269 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          September 27, 2021

                          Lead Product(s) : HS269

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          BioJapan
                          Not Confirmed
                          BioJapan
                          Not Confirmed

                          Details : Favipiravir is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of COVID-19.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          June 11, 2020

                          Lead Product(s) : Favipiravir

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Tigermed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          BioJapan
                          Not Confirmed
                          BioJapan
                          Not Confirmed

                          Details : Favipiravir alleviated the pneumonia symptom of COVID-19 patients with high tolerance and few adverse reactions, potentially through a mechanism that can quickly eliminate the coronaviruses.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          March 19, 2020

                          Lead Product(s) : Favipiravir

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Undisclosed

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          BioJapan
                          Not Confirmed
                          BioJapan
                          Not Confirmed

                          Details : Fapilavir allegedly demonstrated efficacy with minor side effects in an ongoing 70-patient clinical trial in Shenzhen, Guangdong province. The drug’s generic version received the approval.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          February 18, 2020

                          Lead Product(s) : Favipiravir

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Undisclosed

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank